Samsung Bioepis, Genentech settle bevacizumab patent dispute
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
According to sources on Wednesday, the two companies recently entered into a bevacizumab settlement agreement, ending their two-year legal battle over the South Korean biotech company¡¯s submission of marketing approval for SB8, an Avastin biosimilar, in the United States.
In June 2020, Genentech filed a complaint against Samsung Bioepis, alleging infringement of fourteen patents used in the development of Avastin. SB8 is sold by Boryung Pharmaceutical under the brand name of Onbevezy in Korea. Genentech¡¯s reference drug is sold by Roche worldwide under the name of Avastin for the treatment of patients with metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer, among others.
Under the agreement, the indications of SB8 will be further expanded, allowing it to be prescribed to patients with epithelial ovarian cancer and peritoneal cancer.
Onbevezy was launched in Korea in September last year and recorded sales of 6.1 billion won ($4.37 million) in the first half of this year. According to IQVIA data, Onbevezy accounted for 18.5 percent of the bevacizumab product market in the second quarter of this year, up from 8.4 percent in the previous quarter.
[¨Ï Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Four out of 10 Korean stocks defeated in market value during pandemic 3 years - Pulse by Maeil Business News Korea
- Korean panel makers look over their shoulder amid Chinese migration from LCD to OLED - Pulse by Maeil Business News Korea
- Ford mgmt visits LGES, SK in Korea to discuss IRA under solid battery alliance - Pulse by Maeil Business News Korea
- Mirae Asset Global tops commercial property buyer list amid lush offering in Korea - Pulse by Maeil Business News Korea
- Stokke expanding in S. Korea, betting on picky parenting amid bottom birth rate - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 효성그룹 또다시…형제의 난 ‘스멀스멀’
- ‘지역비하’ 피식대학, 구독자 300만 붕괴…20만 명 등 돌렸다(종합)[MK★이슈] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이